公开(公告)号：US20240382442A1

公开(公告)日：2024-11-21

申请号：US18665149

申请日：2024-05-15

Applicant: Bonafide Health, LLC

Inventor： James R. Komorowski ,  Devon Bernsley

IPC: A61K31/198 ,  A61K31/197 ,  A61K31/235 ,  A61K31/685 ,  A61K31/7076 ,  A61K33/06 ,  A61P25/20

Abstract: Disclosed herein are compositions comprising two or more sleep-inducing agonists and/or a sleep-inducing antagonist. The compositions are for promoting healthy sleep quality and treating, ameliorating, preventing, or reducing one or more symptoms associated with menopause. Also described herein are methods utilizing the aforementioned compositions.

公开(公告)号：US20240358727A1

公开(公告)日：2024-10-31

申请号：US18635427

申请日：2024-04-15

Applicant: Northeastern University

Inventor： Kirin D. Gada ,  Leigh D. Plant

IPC: A61K31/683 ,  A61K31/10 ,  A61K31/132 ,  A61K31/137 ,  A61K31/235 ,  A61K31/265 ,  A61K31/27 ,  A61K31/365 ,  A61K31/58 ,  A61K31/685 ,  A61K31/7036 ,  A61P9/06 ,  G01N33/50

CPC classification number: A61K31/683 ,  A61K31/10 ,  A61K31/132 ,  A61K31/137 ,  A61K31/235 ,  A61K31/265 ,  A61K31/27 ,  A61K31/365 ,  A61K31/58 ,  A61K31/685 ,  A61K31/7036 ,  A61P9/06 ,  G01N33/502

Abstract: Voltage-gated sodium (NaV) channels are densely expressed in most excitable cells and activate in response to depolarization, causing a rapid influx of Na+ ions that initiates the action potential. The voltage-dependent activation of NaV channels is followed almost instantaneously by fast inactivation, setting the refractory period of excitable tissues. The gating cycle of NaV channels is subject to tight regulation, with perturbations leading to a range of pathophysiological states. The gating properties of most ion channels are regulated by the membrane phospholipid, phosphatidylinositol (4,5) bisphosphate (PI(4,5)P2). However, it is not known whether PI(4,5)P2 modulates the activity of NaV channels. Here, we utilize optogenetics to activate specific, membrane-associated phosphoinositide (PI)-phosphatases that dephosphorylate PI(4,5)P2 while simultaneously recording NaV1.4 channel currents. We show that dephosphorylating PI(4,5)P2 left-shifts the voltage-dependent gating of NaV1.4 to more hyperpolarized membrane potentials, augments the late current that persists after fast inactivation, and speeds the rate at which channels recover from fast inactivation. These effects are opposed by exogenous diC8PI(4,5)P2. We provide evidence that PI(4,5)P2 is a negative regulator that tunes the gating behavior of NaV1.4 channels.

公开(公告)号：US20240342234A1

公开(公告)日：2024-10-17

申请号：US18634670

申请日：2024-04-12

Applicant: Dreembio S.A.S. ,  NUCAPS NANOTECHNOLOGY, S.L.

Inventor： Susana Fiorentino Gomez ,  Ricardo Ballesteros-Ramirez ,  Claudia Patricia Urueña Pinzón ,  Laura Yinneth Rojas Fonseca ,  Ana Brotons-Canto ,  Izaskun Imbuluzqueta-Iturburua ,  Edurne Luque-Michel ,  Ana Luisa Martinez-Lopez

IPC: A61K36/48 ,  A61K9/51 ,  A61K31/192 ,  A61K31/235

CPC classification number: A61K36/48 ,  A61K9/5123 ,  A61K9/5169 ,  A61K31/192 ,  A61K31/235

Abstract: A P2Et treatment using a casein nanoencapsulation method for significantly delaying tumor growth. The nanoencapeulation leads to higher doses of effective P2Et being delivered, improving bioavailability and biological activity and as such, provides a novel perspective on the delivery of these functional ingredients.

公开(公告)号：US20240277742A1

公开(公告)日：2024-08-22

申请号：US18442146

申请日：2024-02-15

Applicant: CHI BIOTECH CO., LTD.

Inventor： Gong ZHANG ,  Yang CHEN ,  Zhuo YU

IPC: A61K31/7034 ,  A61K31/235 ,  A61K31/58 ,  A61P35/00

CPC classification number: A61K31/7034 ,  A61K31/235 ,  A61K31/58 ,  A61P35/00

Abstract: Provided is a translation inhibitor without occupying ribosome resources. The translation inhibitor without occupying ribosome resources shows a good anti-tumor effect and is highly safe, and can be used in preparation of an anti-tumor drug.

公开(公告)号：US20240269103A1

公开(公告)日：2024-08-15

申请号：US18432291

申请日：2024-02-05

Applicant: Mylan Pharmaceuticals inc.

Inventor： John D. Kirsch ,  Ross A. Friedman

IPC: A61K31/235 ,  A61K9/00 ,  A61K9/20 ,  A61K31/135

CPC classification number: A61K31/235 ,  A61K9/0053 ,  A61K9/2054 ,  A61K31/135

Abstract: The present invention relates to a solid oral pharmaceutical composition that includes: (a) an active pharmaceutical ingredient; (b) a nitrosamine inhibitor that includes linear or branched C1-C10 alkyl 3,4,5-trihydroxybenzoate; and (c) a pharmaceutically acceptable excipient. At least one of: (i) the active pharmaceutical ingredient includes at least one covalently bonded amine group that is subject to conversion to nitrosamine; or (ii) the solid oral pharmaceutical composition includes at least one amine, that is other than the amine group covalently bonded to/within the active pharmaceutical ingredient, and which is subject to conversion to nitrosamine. The nitrosamine inhibitor is present in an amount at least sufficient to reduce the amount of nitrosamine formed in the solid oral pharmaceutical composition, compared to the amount of nitrosamine formed in a comparative solid oral pharmaceutical composition that is free of the nitrosamine inhibitor.

公开(公告)号：US20240238231A1

公开(公告)日：2024-07-18

申请号：US18273754

申请日：2022-01-21

Applicant: Axcess (UK) Ltd

Inventor： Roger R.C. New ,  Glen Travers

IPC: A61K31/198 ,  A61K9/00 ,  A61K31/235 ,  A61K31/575 ,  A61K33/06 ,  A61K45/06

CPC classification number: A61K31/198 ,  A61K9/0056 ,  A61K31/235 ,  A61K31/575 ,  A61K33/06 ,  A61K45/06

Abstract: The present invention relates to methods of preserving the integrity of peptides in the gut. In particular, it concerns the use of certain compounds as inhibitors of gut proteases.

公开(公告)号：US20240189366A1

公开(公告)日：2024-06-13

申请号：US18541250

申请日：2023-12-15

Applicant: Aker BioMarine Human Ingredients AS

Inventor： Inge Bruheim ,  Snorre Tilseth ,  Daniele Mancinelli

IPC: A61K35/612 ,  A23L33/115 ,  A61K9/00 ,  A61K9/48 ,  A61K31/122 ,  A61K31/20 ,  A61K31/202 ,  A61K31/215 ,  A61K31/23 ,  A61K31/235 ,  A61K31/575 ,  A61K31/683 ,  A61K31/685 ,  A61K45/06 ,  C11B3/00

CPC classification number: A61K35/612 ,  A23L33/115 ,  A61K9/0053 ,  A61K9/48 ,  A61K9/4825 ,  A61K9/4858 ,  A61K31/122 ,  A61K31/20 ,  A61K31/202 ,  A61K31/215 ,  A61K31/23 ,  A61K31/235 ,  A61K31/575 ,  A61K31/683 ,  A61K31/685 ,  A61K45/06 ,  C11B3/006 ,  A23V2002/00

Abstract: This invention discloses new krill oil compositions characterized by having high amounts of phospholipids, astaxanthin esters and/or omega-3 contents. The krill oils are obtained from krill meal using supercritical fluid extraction in a two stage process. Stage 1 removes the neutral lipid by extracting with neat supercritical CO2 or CO2 plus approximately 5% of a co-solvent. Stage 2 extracts the actual krill oils by using supercritical CO2 in combination with approximately 20% ethanol. The krill oil materials obtained are compared with commercially available krill oil and found to be more bioeffective in a number of areas such as anti-inflammation, anti-oxidant effects, improving insulin resistances and improving blood lipid profile.

公开(公告)号：US11964955B2

公开(公告)日：2024-04-23

申请号：US17113248

申请日：2020-12-07

Applicant: SYMRISE AG

Inventor： Oskar Koch ,  Marcus Rudolf Götz

IPC: C07D311/80 ,  A61K31/235 ,  A61K31/352 ,  C07C37/50 ,  C07C39/23 ,  C07C67/03 ,  C07C67/343 ,  C07C69/94

CPC classification number: C07D311/80 ,  A61K31/235 ,  A61K31/352 ,  C07C37/50 ,  C07C39/23 ,  C07C67/03 ,  C07C67/343 ,  C07C69/94 ,  A61K2300/00 ,  C07C2601/14 ,  C07C2601/16 ,  A61K31/235 ,  A61K2300/00 ,  A61K31/352 ,  A61K2300/00 ,  C07C67/343 ,  C07C69/94 ,  C07C67/03 ,  C07C69/94 ,  C07C37/50 ,  C07C39/23

Abstract: Described are specific mixtures comprising one or more (cannabinoid) compounds of the formula (A) and/or one or more of their salts as well was methods for their production.




Further described are a compound of the formula (A), a salt of the formula (A) and a corresponding mixture for use as a medicament or, respectively, for use in a method for therapeutic treatment of the human or animal body.
Described are also corresponding pharmaceutical formulations, cosmetic preparations and preparations for pleasure and/or nutrition, suitable for consumption, as well as methods for producing CBDV and THCV.

公开(公告)号：US20240050504A1

公开(公告)日：2024-02-15

申请号：US17885579

申请日：2022-08-11

Applicant: HONG KONG CHINESE MEDICINE OPHTHALMOLOGY INSTITUTE LIMITED

Inventor： See Tung Kwan

IPC: A61K36/28 ,  A61K9/00 ,  A61K36/25 ,  A61K36/808 ,  A61K35/413 ,  A61K36/286 ,  A61K36/59 ,  A61K36/533 ,  A61K47/02 ,  A61K31/235

CPC classification number: A61K36/28 ,  A61K9/0048 ,  A61K36/25 ,  A61K36/808 ,  A61K35/413 ,  A61K36/286 ,  A61K36/59 ,  A61K36/533 ,  A61K47/02 ,  A61K31/235 ,  A61K2236/39 ,  A61K2236/331 ,  A61K2236/53

Abstract: The present invention relates to the preparation technical field of traditional Chinese medicine and more particularly, to a traditional Chinese medicine eye drops and the preparation method thereof. The traditional Chinese medicine components of the traditional Chinese medicine eye drops provided by the embodiments of the invention comprise: ginseng radix et rhizoma of 5-10 wt %, scrophulariae radix of 15-20 wt %, xanthii fructus of 5-10 wt %, bovis calculus sativus of 5-10 wt %, carthami flos of 5-10 wt %, borneolum of 5-10 wt %, senecionis scandentis herba of 25-35 wt %, fibraureae caulis of 5-15 wt % and motherwort fruit of 5-10 wt %.

公开(公告)号：US11865143B2

公开(公告)日：2024-01-09

申请号：US15915439

申请日：2018-03-08

Applicant: AKER BIOMARINE ANTARCTIC AS

Inventor： Inge Bruheim ,  Snorre Tilseth ,  Daniele Mancinelli

IPC: A61K35/612 ,  A61K9/48 ,  A61K31/215 ,  A23L33/115 ,  A61K31/122 ,  A61K31/23 ,  A61K31/683 ,  A61K31/685 ,  A61K45/06 ,  C11B3/00 ,  A61K31/202 ,  A61K31/20 ,  A61K31/235 ,  A61K9/00 ,  A61K31/575

CPC classification number: A61K35/612 ,  A23L33/115 ,  A61K9/0053 ,  A61K9/48 ,  A61K9/4825 ,  A61K9/4858 ,  A61K31/122 ,  A61K31/20 ,  A61K31/202 ,  A61K31/215 ,  A61K31/23 ,  A61K31/235 ,  A61K31/575 ,  A61K31/683 ,  A61K31/685 ,  A61K45/06 ,  C11B3/006 ,  A23V2002/00 ,  A61K31/23 ,  A61K2300/00 ,  A61K31/683 ,  A61K2300/00 ,  A61K31/685 ,  A61K2300/00 ,  A61K31/122 ,  A61K2300/00

Abstract: This invention discloses new krill oil compositions characterized by having high amounts of phospholipids, astaxanthin esters and/or omega-3 contents. The krill oils are obtained from krill meal using supercritical fluid extraction in a two stage process. Stage 1 removes the neutral lipid by extracting with neat supercritical CO2 or CO2 plus approximately 5% of a co-solvent. Stage 2 extracts the actual krill oils by using supercritical CO2 in combination with approximately 20% ethanol. The krill oil materials obtained are compared with commercially available krill oil and found to be more bioeffective in a number of areas such as anti-inflammation, anti-oxidant effects, improving insulin resistances and improving blood lipid profile.